Pfizer
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more
Loading news...
Loading more...
4:38 AM | Saturday | Aug 29, 2026
Sign in to download news snippet
Archer Investment Corp bought a new position in shares of Pfizer Inc. (NYSE: PFE) during the second quarter, according to its most recent filing with the SEC. The fund bought 73,546 shares of the biopharmaceutical company's stock, valued at approximately $1,771,000. Other institutional investors have also recently made changes to their positions in
Read full articleNo data available for this time period.
Change the time range to see results.
Archer Investment Corp bought a new position in shares of Pfizer Inc. (NYSE: PFE) during the second quarter, according to its most recent filing with the SEC. The fund bought 73,546 shares of the biopharmaceutical company's stock, valued at approximately $1,771,000. Other institutional investors have also recently made changes to their positions in
Read full article
A single trial readout is reshuffling the mRNA vaccine trade this morning. BioNTech SE (NASDAQ:BNTX | BNTX Price Prediction) stock is down 8% to $102.
Read full article
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Read full article
Pfizer's management is standing behind the company's dividend. Although earnings aren't covering the payment, the drug giant has ample cash to pay it, for now.
Read full article
Algert Global LLC raised its holdings in shares of Pfizer Inc. (NYSE: PFE) by 824.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 343,130 shares of the biopharmaceutical company's stock after buying an additional 305,997 shares during
Read full article
Bank of Nova Scotia lessened its holdings in Pfizer Inc. (NYSE: PFE) by 13.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,423,296 shares of the biopharmaceutical company's stock after selling 683,496 shares during the quarter. Bank of
Read full article
Our 24/7 Wall St. price target for Pfizer (NYSE:PFE | PFE Price Prediction) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07.
Advisors Capital Management LLC raised its holdings in shares of Pfizer Inc. (NYSE: PFE) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,703,246 shares of the biopharmaceutical company's stock after purchasing an additional 73,540 shares during the quarter.
Read full article
Danske Bank A S boosted its position in Pfizer Inc. (NYSE: PFE) by 9.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,677,679 shares of the biopharmaceutical company's stock after buying an additional 309,400 shares during the quarter. Danske Bank A
Read full article
Danske Bank A S boosted its position in Pfizer Inc. (NYSE: PFE) by 9.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,677,679 shares of the biopharmaceutical company's stock after buying an additional 309,400 shares during the quarter. Danske Bank A
Read full article
No data available for this time period.
Change the time range to see results.